Literature DB >> 7508864

Anti-inflammatory effects of glucocorticoids and cyclosporin A on human basophils.

G Marone1, C Stellato, A Renda, A Genovese.   

Abstract

Pro-inflammatory and vasoactive mediators released from human basophils and mast cells play a role in several inflammatory and immune disorders. It was recently demonstrated that cyclosporin A (CsA) exerts anti-inflammatory effects by inhibiting the release of preformed and de novo synthesized mediators from human basophils. This study compared the effects of pharmacological concentrations of deflazacort (DFZ) and prednisolone (PRED) on the anti-IgE-mediated release of preformed (histamine) and de novo synthesized (leukotriene C4: [LTC4]) mediators from basophils. Basophils were cultured for 18 hours in the presence of pharmacological concentrations of DFZ (10(-8) to 3 x 10(-6) M). DFZ inhibited the anti-IgE-mediated release of histamine and LTC4 from basophils in a concentration-dependent manner (6-40%), and had a similar efficacy and potency to PRED. The effect of DFZ (10(-8) to 10(-7) M) in combination with CsA on the immunological release of histamine and LTC4 from basophils was also evaluated. An 18-hour incubation of basophils with DFZ (10(-8) M) followed by a short (15-minute) incubation with CsA (30 ng/ml) resulted in an additive inhibition of the release of histamine and LTC4. The additive anti-inflammatory effect of these drugs makes them interesting candidates for future controlled clinical trials in inflammatory diseases in which basophil-derived mediators play a relevant role.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7508864     DOI: 10.1007/bf01844198

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  27 in total

1.  Topical use of cyclosporine in the treatment of vernal keratoconjunctivitis.

Authors:  A G Secchi; M S Tognon; A Leonardi
Journal:  Am J Ophthalmol       Date:  1990-12-15       Impact factor: 5.258

2.  Cyclosporin A rapidly inhibits mediator release from human basophils presumably by interacting with cyclophilin.

Authors:  R Cirillo; M Triggiani; L Siri; A Ciccarelli; G R Pettit; M Condorelli; G Marone
Journal:  J Immunol       Date:  1990-05-15       Impact factor: 5.422

3.  Human basophil releasability. II. Changes in basophil releasability in patients with atopic dermatitis.

Authors:  G Marone; R Giugliano; G Lembo; F Ayala
Journal:  J Invest Dermatol       Date:  1986-07       Impact factor: 8.551

4.  Human basophil/mast cell releasability. V. Functional comparisons of cells obtained from peripheral blood, lung parenchyma, and bronchoalveolar lavage in asthmatics.

Authors:  V Casolaro; D Galeone; A Giacummo; A Sanduzzi; G Melillo; G Marone
Journal:  Am Rev Respir Dis       Date:  1989-06

5.  Human basophil releasability. VIII. Increased basophil releasability in patients with scleroderma.

Authors:  A de Paulis; G Valentini; G Spadaro; S Lupoli; G Tirri; G Marone
Journal:  Arthritis Rheum       Date:  1991-10

6.  Human basophil releasability. VI. Changes in basophil releasability in patients with allergic rhinitis or bronchial asthma.

Authors:  V Casolaro; G Spadaro; G Marone
Journal:  Am Rev Respir Dis       Date:  1990-11

7.  Overview of corticosteroid therapy.

Authors:  S C Siegel
Journal:  J Allergy Clin Immunol       Date:  1985-08       Impact factor: 10.793

8.  Inhibition of human basophil leukotriene release by antiinflammatory steroids.

Authors:  R P Schleimer; D A Davidson; S P Peters; L M Lichtenstein
Journal:  Int Arch Allergy Appl Immunol       Date:  1985

9.  Trial of cyclosporin in corticosteroid-dependent chronic severe asthma.

Authors:  A G Alexander; N C Barnes; A B Kay
Journal:  Lancet       Date:  1992-02-08       Impact factor: 79.321

10.  Factors associated with early remission of type I diabetes in children treated with cyclosporine.

Authors:  P F Bougneres; J C Carel; L Castano; C Boitard; J P Gardin; P Landais; J Hors; M J Mihatsch; M Paillard; J L Chaussain
Journal:  N Engl J Med       Date:  1988-03-17       Impact factor: 91.245

View more
  3 in total

1.  Interferons up-regulate with different potency HLA class I antigen expression in M14 human melanoma cell line. Possible interaction with glucocorticoid hormones.

Authors:  L Lanza; L Peirano; O Bosco; P Contini; G Filaci; M Setti; F Puppo; F Indiveri; M Scudeletti
Journal:  Cancer Immunol Immunother       Date:  1995-07       Impact factor: 6.968

2.  Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes.

Authors:  L Lanza; M Scudeletti; F Puppo; O Bosco; L Peirano; G Filaci; E Fecarotta; G Vidali; F Indiveri
Journal:  Clin Exp Immunol       Date:  1996-03       Impact factor: 4.330

Review 3.  The Evolution of Human Basophil Biology from Neglect towards Understanding of Their Immune Functions.

Authors:  Markus Steiner; Sara Huber; Andrea Harrer; Martin Himly
Journal:  Biomed Res Int       Date:  2016-12-19       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.